Subsequent Event	6 Months Ended
May 31, 2026
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On June 6, 2026, the Company entered into a global collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (together, Roche), to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948) (the Roche Collaboration Agreement). Under the terms of the Roche Collaboration Agreement, the Company will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestone payments for potential total payments of up to $2.3 billion, including the upfront payment. Global development costs will be shared 40% by the Company and 60% by Roche, subject to specified exceptions. The parties will equally split the profits and losses from U.S. commercialization. The Company and Roche will co-commercialize bexobrutideg in the United States across all indications. Outside of the United States, Roche will be responsible for commercialization, and the Company is eligible to receive tiered royalties at rates ranging from the low teens to the high teens on ex-U.S. sales. The Roche Collaboration Agreement will become effective upon the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the expiration, termination or resolution of all other required waiting periods, clearance decisions or outstanding inquiries under antitrust laws.

Subsequent Event

6 Months Ended

May 31, 2026

On June 6, 2026, the Company entered into a global collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (together, Roche), to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948) (the Roche Collaboration Agreement). Under the terms of the Roche Collaboration Agreement, the Company will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestone payments for potential total payments of up to $2.3 billion, including the upfront payment. Global development costs will be shared 40% by the Company and 60% by Roche, subject to specified exceptions. The parties will equally split the profits and losses from U.S. commercialization. The Company and Roche will co-commercialize bexobrutideg in the United States across all indications. Outside of the United States, Roche will be responsible for commercialization, and the Company is eligible to receive tiered royalties at rates ranging from the low teens to the high teens on ex-U.S. sales. The Roche Collaboration Agreement will become effective upon the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the expiration, termination or resolution of all other required waiting periods, clearance decisions or outstanding inquiries under antitrust laws.